Chemkart India H2 FY26: The Volatility of Nutraceutical Ingredients and a Chairman’s Bail Bond
Section 1 — At a Glance
Chemkart India Ltd reported a consolidated revenue from operations of ₹214.83 crore for the full fiscal year ended March 31, 2026, marking a modest top-line growth of 5.68% compared to ₹203.28 crore in the previous fiscal year. However, this expansion came at a steep operational cost, as Consolidated Profit After Tax (PAT) plummeted by 19.00% to ₹19.66 crore down from ₹24.27 crore in FY25. This compression is vividly highlighted by the company’s EBITDA, which fell 14.30% to ₹28.18 crore for the full year, pulling down EBITDA margins from 16.2% to 13.1%.
Investors are actively tracking the aggressive transition from a pure-play B2B trading model to an integrated contract development and manufacturing organization (CDMO) format. The company raised ₹80 crore through its listing on the BSE SME platform on July 14, 2025, earmarking ₹65 crore of fresh issue proceeds predominantly for setting up an export-oriented nutraceutical facility at the JNPA SEZ under its subsidiary, Easy Raw Materials Pvt. Ltd (EZRM).
While the virtual eradication of short-term liabilities and a massive cash buffer of ₹38.65 crore comfort the risk-averse, significant governance and structural headwinds are keeping the market deeply anxious. The sudden arrest and subsequent bail of the Chairman by the Directorate of Revenue Intelligence (DRI) in December 2025 over import classification disputes—resulting in a multi-crore duty assessment—shattered initial listing stability. When structural regulatory investigations hit a trading operation, operational agility is quickly tested. The primary teaser for the coming quarters remains whether the commercialization of the SEZ facility can rebuild the company’s eroded margins.
Section 2 — Introduction
Chemkart India Limited entered the public market with a business model heavily centered around the distribution of raw nutraceutical ingredients. Founded in 2015 as a proprietorship and corporatized in 2020, the Mumbai-headquartered microcap operates inside a booming domestic wellness space. The company operates a core 28,259 sq. ft. processing and warehousing hub in Bhiwandi, Thane, acting as a key logistical bridge for manufacturers of dietary and wellness supplements across the country.
The publication of the H2 FY26 and full-year results becomes a critical analytical juncture for the market. Chemkart is attempting to break free from the low-margin constraints of pure distribution by stepping into advanced backward integration. However, this pivot is being executed under a cloud of regulatory scrutiny. For high-growth microcaps, public capital accelerates development, but it also brings maximum exposure when supply chains or management actions miss the mark. This deep dive untangles the underlying asset health from the corporate drama.
Section 3 — Business Model: WTF Do They Even Do?
At its core, Chemkart is a gatekeeper for raw materials that go into performance shakes, vitamins, and health supplements. The business runs on two highly unequal legs: a massive trading operation and a tiny, nascent processing segment. The trading business historically accounts for 97% of operational revenues. Chemkart sources bulk amino acids (like Creatine Monohydrate, L-Glutamine, and BCAA 2:1:1), herbal extracts, and proteins from international suppliers and distributes them to domestic B2B supplement brands.
The second leg is an in-house processing segment contributing just 3% of revenues. This involves basic blending and grinding capabilities at their Bhiwandi plant to provide custom formulations.
Geographically, this is an entirely domestic play, with 98.80% of revenue derived from the Indian market. The customer base exhibits moderate concentration, with the top 10 buyers generating nearly half of total sales at 48.44%. This effectively makes Chemkart an intermediary taking inventory price risks on bulk imports while fighting to retain volume share among local contract manufacturers.
